Idioma:

Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing

Rosenstock, Julio ; Reusch, Jane ; Bush, Mark ; Yang, Fred ; Stewart, Murray

Diabetes care, 2009-10, Vol.32 (10), p.1880-1886 [Periódico revisado por pares]

Alexandria, VA: American Diabetes Association

Texto completo disponível

Citações Citado por

Enviar para

Título:
Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing
Autor: Rosenstock, Julio ; Reusch, Jane ; Bush, Mark ; Yang, Fred ; Stewart, Murray
Assuntos: Biological and medical sciences ; Clinical trials ; Data analysis ; Diabetes ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes. Impaired glucose tolerance ; Double-Blind Method ; Drug Administration Schedule ; Early intervention ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Glucagon-Like Peptide 1 - administration & dosage ; Glucagon-Like Peptide 1 - analogs & derivatives ; Glucagon-Like Peptide 1 - therapeutic use ; Glucagon-Like Peptide-1 Receptor ; Humans ; Hypoglycemic Agents - administration & dosage ; Hypoglycemic Agents - therapeutic use ; Medical sciences ; Metabolic diseases ; Miscellaneous ; Multicenter Studies as Topic ; Original Research ; Placebo Effect ; Public health. Hygiene ; Public health. Hygiene-occupational medicine ; Receptors, Glucagon - agonists ; Studies ; Treatment Outcome
É parte de: Diabetes care, 2009-10, Vol.32 (10), p.1880-1886
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-News-1
ObjectType-Feature-3
Descrição: OBJECTIVE: To evaluate the efficacy, safety, and tolerability of incremental doses of albiglutide, a long-acting glucagon-like peptide-1 receptor agonist, administered with three dosing schedules in patients with type 2 diabetes inadequately controlled with diet and exercise or metformin monotherapy. RESEARCH DESIGN AND METHODS: In this randomized multicenter double-blind parallel-group study, 356 type 2 diabetic subjects with similar mean baseline characteristics (age 54 years, diabetes duration 4.9 years, BMI 32.1 kg/m², A1C 8.0%) received subcutaneous placebo or albiglutide (weekly [4, 15, or 30 mg], biweekly [15, 30, or 50 mg], or monthly [50 or 100 mg]) or exenatide twice daily as an open-label active reference (per labeling in metformin subjects only) over 16 weeks followed by an 11-week washout period. The main outcome measure was change from baseline A1C of albiglutide groups versus placebo at week 16. RESULTS: Dose-dependent reductions in A1C were observed within all albiglutide schedules. Mean A1C was similarly reduced from baseline by albiglutide 30 mg weekly, 50 mg biweekly (every 2 weeks), and 100 mg monthly (-0.87, -0.79, and -0.87%, respectively) versus placebo (-0.17%, P < 0.004) and exenatide (-0.54%). Weight loss (-1.1 to -1.7 kg) was observed with these three albiglutide doses with no significant between-group effects. The incidence of gastrointestinal adverse events in subjects receiving albiglutide 30 mg weekly was less than that observed for the highest biweekly and monthly doses of albiglutide or exenatide. CONCLUSIONS: Weekly albiglutide administration significantly improved glycemic control and elicited weight loss in type 2 diabetic patients, with a favorable safety and tolerability profile.
Editor: Alexandria, VA: American Diabetes Association
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing

Rosenstock, Julio ; Reusch, Jane ; Bush, Mark ; Yang, Fred ; Stewart, Murray

Alexandria, VA: American Diabetes Association

Buscando em bases de dados remotas. Favor aguardar.